CeraVe Skin Care Line for Mild to Severe Acne
This observational study examines the effectiveness of the CeraVe Skin Care Line for mild to severe acne. Participants' skin conditions will be evaluated using the Global Evaluation Acne Grading scale, physician assessments, and self-assessment questionnaires on quality of life.
Data Collection
Collected from today forward - ProspectiveAcne Vulgaris+2
+ Sebaceous Gland Diseases
+ Skin Diseases
Cohort
Tracking disease incidence in order to identify risk factors and understand disease progression over time.Summary
Study start date: June 27, 2025
Actual date on which the first participant was enrolled.This clinical study aims to observe and evaluate how effective CeraVe Skin Care products are in improving facial acne, ranging from mild to severe cases. The study involves about 240 participants, both male and female, who are 13 years or older and have varying levels of facial acne severity. The goal is to see how well these products work and to gather feedback on the user's quality of life and satisfaction with the products. This study is important because it may help provide a better understanding of how CeraVe products can be used to manage acne and improve skin condition, potentially offering a valuable skincare option for those affected by this common skin issue. Participants in the study use the CeraVe skincare kit over an 8-week period, visiting the dermatologist at the start, at 4 weeks, and at 8 weeks. Dermatologists assess the participants' skin condition using a Global Evaluation Acne Grading Scale before and after using the products. Participants also fill out self-assessment questionnaires about their quality of life and their experiences with acne. The study measures improvements in acne severity, evaluates how well participants tolerate the skincare products, and assesses any changes in their quality of life. This comprehensive approach ensures a detailed understanding of the products' efficacy and safety.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.240 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Cohort
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 13 Years
Range of ages for which participants are eligible to join.Conditions
Pathology
Criteria
Inclusion Criteria: * Chinese males and females, age eligible greater than or equal to 13 years old; * Be in good health and free from any other chronic disease or disease under treatment; * Be judged by a dermatologist at the Baseline visit: Mild, moderate, or severe acne according to the Global Evaluation Acne Grading Scale (GEA)11,12 (Mild - Grade 1 or Grade 2) Acne Grading Scale (GEA) - Scale 1 or 2, Moderate - Scale 3, Severe - Scale 4 or above); * Initiation of acne treatment within the last 3 months with medications that include, but are not limited to, the following 1. Topical medications: benzoyl peroxide (BPO), retinoic acid, adapalene, isotretinoin, azelaic acid, 0.1% adapalene/BPO. b) Topical medications: benzoyl peroxide (BPO), retinoic acid, adapalene, isotretinoin, azelaic acid, adapalene 0.3% adapalene/BPO, retinoic acid/clindamycin, BPO/clindamycin; 2. Oral medications: antibiotics, spironolactone, isotretinoin, etc; If Global Evaluation Acne Grading Scale (GEA) classification is ≥2, continuous use of the above medications for at least 2 weeks prior to the baseline visit is required. If the Global Evaluation Acne Grading Scale (GEA) is ≥2, acne treatment with the above medications should be continued for at least 2 weeks before the baseline visit; If oral medication is used, acne treatment should be continued for at least 4 weeks prior to the baseline visit. Exclusion Criteria: * Adult female study participants who intend to plan a pregnancy, or who are pregnant, breastfeeding, within 6 months of delivery, or who are unwilling to take the necessary precautions to avoid pregnancy; * Study participants who are currently enrolled in another clinical study or have been enrolled in another clinical study within 3 months; * Study participants who have undergone physical, chemical, or cosmetic surgery within 3 months prior to enrollment; * Systemic diseases with severe organ damage, cardiovascular diseases, liver or kidney dysfunction, malignant tumors, chronic diseases with unstable control, acute infectious diseases, major surgeries or traumas, psychological and psychiatric disorders, or other diseases that require topical or systemic use of medications or treatments that have an effect on acne; * The study site is associated with other skin disorders (atopic dermatitis, rosacea, rosacea, eczema, etc.) or the presence of other skin conditions that interfere with evaluation (birthmarks, scarring, etc.); * Participants in the study have a history of allergic contact dermatitis caused by cleansers (facial cleansers)/moisturizers; * History of allergy or severe allergy to the products (Sensitive Skin products) and related ingredients provided in the study; * Study participants who are unable to follow compliance requirements, or who are known to be unable to attend visits on time, or who are unwilling to comply with the study protocol arrangements for the duration of the study; * Any clinical presentation or other illness in the required observation area that, in the opinion of the investigator, may affect the study product assessment or results. * Study participants had received medical aesthetic treatments (including but not limited to photofacial type treatments, fruit acid resurfacing, etc.) within 3 months prior to enrollment.
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Study Objectives
Primary Objectives
Secondary Objectives